{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:26:58Z","timestamp":1778002018149,"version":"3.51.4"},"reference-count":137,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/17425255.2019.1667334","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T07:41:51Z","timestamp":1568274111000},"page":"787-802","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Drug-drug interactions when treating HIV-related metabolic disorders"],"prefix":"10.1080","volume":"15","author":[{"given":"Maria del Mar","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Gracia","family":"Mateo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Corbacho","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Vidal","sequence":"additional","affiliation":[{"name":"HIV Infection Unit, Department of Internal Medicine, Hospital Universitari Joan XXIII, Institut de Recerca Rovira i Virgili","place":["Tarragona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir627"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu701"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1540"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504075"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr248"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3040745"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0855-8"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.558839"},{"key":"e_1_3_4_12_1","first-page":"1179","article-title":"Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy","volume":"26","author":"Szklarz GD","year":"1998","unstructured":"Szklarz GD, Halpert JR. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos. 1998;26:1179\u20131184.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_4_13_1","volume-title":"Summary of product characteristics","author":"Isentress (raltegravir)","year":"2014","unstructured":"Isentress (raltegravir). Summary of product characteristics. Netherlands: Merck Sharp & Dohme B.V.; 2014 May 14. Revised 2019 Mar 31."},{"key":"e_1_3_4_14_1","volume-title":"Summary of product characteristics","author":"Tivicay (Dolutegravir)","year":"2018","unstructured":"Tivicay (Dolutegravir). Summary of product characteristics. Netherlands: ViiV Healthcare BV; 2018 August 27"},{"key":"e_1_3_4_15_1","volume-title":"Summary of product characteristics","author":"Bictarvy (Bictegravir, emtricitabine, tenofovir alafenamide fumarate)","year":"2018","unstructured":"Bictarvy (Bictegravir, emtricitabine, tenofovir alafenamide fumarate). Summary of product characteristics. Ireland: Gilead Sciences Ireland UC; 2018 June 21."},{"key":"e_1_3_4_16_1","volume-title":"Summary of product characteristics","author":"Genvoya (Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide fumarate)","year":"2015","unstructured":"Genvoya (Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide fumarate). Summary of product characteristics. Ireland: Gilead Sciences International Ltd; 2015 November 19."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.06.007"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9924-0"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018877803319"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04398.x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-013-0013-7"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017717018"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18567"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S184642"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0497-3"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1081993"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03133.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001708"},{"key":"e_1_3_4_29_1","unstructured":"HIVdruginteractions.org [Internet]. University of Liverpool [cited 2019 Feb\u2013Apr]. Available from: http:\/\/www.hiv-druginteractions.org"},{"key":"e_1_3_4_30_1","unstructured":"Interaccioneshiv.com [Internet]. Hospital cl\u00ednic \u2013 IDIBAPS. Barcelona. [cited 2019 Feb\u2013Apr]. Available from: http:\/\/www.interaccioneshiv.com"},{"key":"e_1_3_4_31_1","unstructured":"Hivmedicationguide.com [Internet]. Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM). Quebec Canada [cited 2019 July\u2013Aug]. Available from www.hivmedicationguide.com"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00010"},{"key":"e_1_3_4_33_1","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld C","year":"1992","unstructured":"Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045\u20131052.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318042d5fe"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0806479"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/187153009789044383"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050203"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000437171.00504.41"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0075-4"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0222-7"},{"key":"e_1_3_4_41_1","first-page":"e010345","article-title":"Trends in utilization of statin therapy and contraindicated statin use in HIV-infected adults treated with antiretroviral therapy from 2007 through 2015","volume":"7","author":"Rosenson RS","year":"2018","unstructured":"Rosenson RS, Colantonio LD, Burkholder GA, et al. Trends in utilization of statin therapy and contraindicated statin use in HIV-infected adults treated with antiretroviral therapy from 2007 through 2015. JAmHeartAssoc. 2018;7:e010345.","journal-title":"JAmHeartAssoc"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"e_1_3_4_43_1","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2019 Apr 16]. Available from: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3445-3450.2001"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00008"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/108729100318091"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1086\/344179"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.8.728"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000167156.44980.33"},{"key":"e_1_3_4_50_1","unstructured":"Carr RA Andre RJ Bertz RJ et al. Concomitant administration of ABT 378\/ritonavir results in clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17\u201320; Toronto Canada. Abstract 1644."},{"key":"e_1_3_4_51_1","unstructured":"Wire MB Baker KL Moore KHP et al. The pharmacokinetic (PK) interaction of GW433908 (908) with atorvastatin (ATO) and 908\/ritonavir (RTV) with ATO (APV10013). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sept 14\u201317; Chicago Illinois. Abstract #A-1622."},{"key":"e_1_3_4_52_1","unstructured":"Hoetelmans R Lasure A Koester A et al. The effect of TMC114 a potent next-generation HIV protease inhibitor with low-dose ritonavir on atorvastatin pharmacokinetics. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct. 30\u2013Nov. 2; Washington USA. Poster H-865."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016208786501481"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/108729103321655854"},{"key":"e_1_3_4_55_1","unstructured":"Scholler-Gyure M Kakuda TN De Smedt G et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor TMC125 and atorvastatin in HIV-negative volunteers. 4th IAS Conference on HIV Pathogenesis Treatment & Prevention; 2007 July; Sydney. abstract WEPEA106."},{"key":"e_1_3_4_56_1","doi-asserted-by":"crossref","unstructured":"Van Heeswijk RPG Hoetelmans RMW Aharchi F et al. The pharmacokinetic interaction between atorvastatin and TMC278 a next generation non-nucleoside reverse transcriptase inhibitor in HIV-negative volunteers. 11th European AIDS Conference; 2007 October; Madrid. abstract P4.3\/04.","DOI":"10.1186\/1758-2652-11-S1-P239"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80336-3"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01454-0"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31817b5b5a"},{"key":"e_1_3_4_60_1","unstructured":"Hoody DW Kiser JJ Predhomme J. et al. Drug-drug interaction between lopinavir\/ritonavir and rosuvastatin. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25\u201328; Los Angeles California. Poster 564."},{"key":"e_1_3_4_61_1","unstructured":"Fichtenbaum C Samineni D Moore E et al. Darunavir\/ritonavir increases rosuvastatin concentrations but does not alter lipid-lowering effect in healthy volunteers. 18th International AIDS Conference; 2010July 18\u201323; Vienna Austria. Poster WePE0101."},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.256"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00658-3"},{"key":"e_1_3_4_64_1","unstructured":"Sekar VJ Spinosa-Guzman S Marien K et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 April; Budapest. abstract 54."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011427907"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d9a354"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.589433"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318251addb"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000333"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0198-x"},{"key":"e_1_3_4_71_1","volume-title":"Summary of product characteristics","author":"Reyataz (Atazanavir)","year":"2009","unstructured":"Reyataz (Atazanavir). Summary of product characteristics. Dublin, Ireland: Bristol-Myers Squibb Company; 2009 March 2. revised 2019 Mar 31."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1227791"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181b0610e"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-004-9011-5"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1682"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S33664"},{"key":"e_1_3_4_77_1","volume-title":"Summary of product characteristics","author":"Juxtapid (Lomitapide)","year":"2018","unstructured":"Juxtapid (Lomitapide). Summary of product characteristics. Ireland: Amryt Pharmaceuticals DAC; 2018 Apr 23. revised 2019 Jul 18."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12612"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283559b22"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110386"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.015495"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534750-000000000-00000"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.4.415"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.04.010"},{"key":"e_1_3_4_86_1","volume-title":"Summary of product characteristics","author":"Evotaz","year":"2018","unstructured":"Evotaz Summary of product characteristics. Bristol-Myers Squibb Pharmaceuticals Ltd; 2018 November."},{"key":"e_1_3_4_87_1","unstructured":"Rezolsta Summary of Product Characteristics Janssen-CilagLtd June 2018."},{"key":"e_1_3_4_88_1","unstructured":"Zhang H West S Vu A et al. Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; 2017 June; Chicago. abstract P50."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001617"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001720"},{"key":"e_1_3_4_91_1","first-page":"71","article-title":"Pharmacokinetics and metabolism of gliclazide. A review","volume":"20","author":"Campbell DB","year":"1980","unstructured":"Campbell DB, Adriaenssens PI, Hopkins YW, et al. Pharmacokinetics and metabolism of gliclazide. A review. Royal Soc Med Int Congr Symp. 1980;20:71\u201382.","journal-title":"Royal Soc Med Int Congr Symp"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.706"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.4.710"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8525"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200017050-00007"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241070-00002"},{"key":"e_1_3_4_97_1","first-page":"415","article-title":"Pharmacokinetics and metabolism of nateglinide in humans","volume":"29","author":"Weaver ML","year":"2001","unstructured":"Weaver ML, Orwig BA, Rodriguez LC, et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos. 2001;29:415\u2013421.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_4_98_1","article-title":"A Comparative review of DPP\u20104 inhibitors and sulphonylureas","volume":"18","author":"Deacon CF","year":"2015","unstructured":"Deacon CF, Lebovitz HE. A Comparative review of DPP\u20104 inhibitors and sulphonylureas. Diabetes Obes Metab. 2015;18:333\u201047.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.03.004"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0061-3"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0547-1"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.944862"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0421-4"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.2165\/11630900-000000000-00000"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.2165\/11598080-000000000-00000"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0169-1"},{"key":"e_1_3_4_109_1","unstructured":"Sitagliptina (Januvia\u00ae) Merck Sharp & Dohme Ltd. 2018. [cited 2019 Aug]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/januvia-epar-product-information_en.pdf"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-018-0038-0"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12926"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1281246"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3321"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S75452"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0343-6"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2011.8.348"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1271779"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_232_19"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0089-4"},{"key":"e_1_3_4_122_1","unstructured":"Farxiga [dapagliflozin]. Summary of product characteristics. [cited 2019 Aug 25]. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2017."},{"key":"e_1_3_4_123_1","unstructured":"Jardiance [empagliflozin]. Summary of product characteristics. 19. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2016."},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0285-z"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S77754"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0104-3"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70266-8"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.360"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-69737-6_13"},{"key":"e_1_3_4_131_1","unstructured":"Videx Prescribing Information Bristol-Myers Squibb Co December 2018."},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161356.ESGL"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281361"},{"key":"e_1_3_4_134_1","volume-title":"Orlistat. StatPearls [Internet]","author":"Bansal AB","year":"2019","unstructured":"Bansal AB, Al Khalili Y. Orlistat. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 [Last Update 2019 Aug 3]."},{"key":"e_1_3_4_135_1","first-page":"525","article-title":"A selective serotonin 5-HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson A, King C, Rey JA. Lorcaserin (Belviq)","year":"2013","unstructured":"Gustafson A, King C, Rey JA. Lorcaserin (Belviq). A selective serotonin 5-HT2C agonist in the treatment of obesity. P T. 2013;38:525\u2013534.","journal-title":"P T"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808721"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00056-0"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.897327"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2019.1667334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:49:40Z","timestamp":1772743780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2019.1667334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/17425255.2019.1667334"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2019.1667334","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}